Earlier this year, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) initiated discussions with the FDA for the design of a registrational study for its experimental drug REC-4881 in familial adenomatous polyposis (FAP), which represents a new way of treating this rare genetic condition without immediate surgery.



 • Recursion Pharmaceuticals shares are retreating from recent levels. Why is RXRX stock falling?



The company is scheduled to provide an update about the FDA decision in the second half of the year. And, there is potential upside to the stock, according to Needham.



The Recursion Pharmaceuticals Analyst: Analyst Gil Blum maintained a Buy rating and price target of $8.



The Recursion Pharmaceuticals Thesis: The company reported non-GAAP operating expenditure of $85 million for the first quarter, representing a decline of around 30% year-on-year, with a fiscal year cash burn guidance of less than $390 million, Blum said in the note.



Check out other analyst stock ratings.



The update on the pivotal trial design for REC-4881 will be the &#34;next value driver&#34; for Recursion Pharmaceuticals, the analyst stated.



&#34;Given the lack of regulatory precedent in FAP, Recursion intends to focus on natural history data, identification of appropriate patient populations, optimizing dose escalation, and defining clinically meaningful endpoints,&#34; Blum wrote.



The company intends to leverage its AI-enabled clinical platform to support registrational planning and accelerate enrolment, he added.



&#34;Recursion also reported initial REC-1245 safety and PK data across four dose cohorts, showing mostly low-grade AEs (adverse events),&#34; the analyst further noted.



RXRX Price Action: Shares of Recursion Pharmaceuticals had declined by 3.85% to $3.30 at the time of publication on Thursday.



<div>



Read Also:

What's Behind The Jump In Recursion Pharmaceuticals Stock?



</div>

RXRX

LABU

Recursion Pharmaceuticals is set to update on the FDA trial design for its drug REC-4881 for familial adenomatous polyposis (FAP) in late 2026. Despite potential upside from rare diseases, shares have fallen 3.85% to $3.30. Analyst Gil Blum maintains a Buy rating with a price target of $8, citing a 30% year-on-year decline in operating expenditure. The pivotal trial design update is expected to be a key value driver, focusing on patient populations and dose optimization, supported by AI-enabled clinical platforms.

benzinga_article

Recursion Pharmaceuticals

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

iShares US Pharma

VG Health

SPDR S&P Biotech

iShares Biotechnology ETF

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back